BioLine Rx Ltd (BLRX)
0.68
+0.02
(+3.01%)
USD |
NASDAQ |
May 03, 16:00
0.6783
0.00 (0.00%)
After-Hours: 20:00
BioLine Rx Cash from Investing (Quarterly): -20.40M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -20.40M |
| September 30, 2023 | 4.097M |
| June 30, 2023 | 11.10M |
| March 31, 2023 | 6.642M |
| December 31, 2022 | 3.862M |
| September 30, 2022 | -14.94M |
| June 30, 2022 | 10.03M |
| March 31, 2022 | 5.048M |
| December 31, 2021 | 3.998M |
| September 30, 2021 | 0.04M |
| June 30, 2021 | -6.001M |
| March 31, 2021 | -36.26M |
| December 31, 2020 | 8.543M |
| September 30, 2020 | 7.542M |
| June 30, 2020 | -5.608M |
| March 31, 2020 | 6.191M |
| December 31, 2019 | 3.191M |
| September 30, 2019 | 5.188M |
| June 30, 2019 | 6.191M |
| March 31, 2019 | -9.313M |
| December 31, 2018 | -6.442M |
| September 30, 2018 | 5.225M |
| June 30, 2018 | 2.688M |
| March 31, 2018 | 8.084M |
| December 31, 2017 | 3.605M |
| Date | Value |
|---|---|
| September 30, 2017 | -3.532M |
| June 30, 2017 | -17.37M |
| March 31, 2017 | 1.367M |
| December 31, 2016 | 1.983M |
| September 30, 2016 | 3.124M |
| June 30, 2016 | 2.536M |
| March 31, 2016 | 1.654M |
| December 31, 2015 | 3.106M |
| September 30, 2015 | -0.833M |
| June 30, 2015 | 2.797M |
| March 31, 2015 | -20.67M |
| December 31, 2014 | -4.109M |
| September 30, 2014 | -0.15M |
| June 30, 2014 | 3.586M |
| March 31, 2014 | -19.06M |
| December 31, 2013 | -0.4155M |
| September 30, 2013 | 0.967M |
| June 30, 2013 | 6.12M |
| March 31, 2013 | -11.99M |
| December 31, 2012 | 9.873M |
| September 30, 2012 | 1.342M |
| June 30, 2012 | -3.413M |
| March 31, 2012 | 5.940M |
| December 31, 2011 | 3.680M |
| September 30, 2011 | 1.628M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-36.26M
Minimum
Mar 2021
11.10M
Maximum
Jun 2023
-0.0808M
Average
4.097M
Median
Sep 2023
Cash from Investing (Quarterly) Benchmarks
| Compugen Ltd | -- |
| Pluri Inc | 3.919M |
| XTL Biopharmaceuticals Ltd | -- |
| Can Fite Biofarma Ltd | -- |
| BiomX Inc | -0.006M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 4.991M |
| Cash from Financing (Quarterly) | 11.74M |
| Free Cash Flow | -22.90M |
| Free Cash Flow Per Share (Quarterly) | 0.0692 |
| Free Cash Flow to Equity (Quarterly) | 6.736M |
| Free Cash Flow Yield | -52.45% |